PubMed (MeSH Keyword) for id: 44148067

Year	Number of Results
2004	3
2005	3
2006	3
2007	7
2008	1
2009	5
2010	7
2011	12
2012	18
2013	12
2014	22
2015	22
2016	28
2017	27
2018	23
2019	13
2020	22
2021	15
2022	10
2023	8
2024	2

1

Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.

Haupts MR, Essner U, Mäurer M. Haupts MR, et al. Neurodegener Dis Manag. 2024 Feb;14(1):11-20. doi: 10.2217/nmt-2023-0040. Epub 2024 Feb 6. Neurodegener Dis Manag. 2024. PMID: 38318862 Free article. Clinical Trial.

2

Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.

Kleiner D, Horváth IL, Bunduc S, Gergő D, Lugosi K, Fehérvári P, Hegyi P, Csupor D. Kleiner D, et al. Curr Neuropharmacol. 2023;21(12):2505-2515. doi: 10.2174/1570159X21666230727094431. Curr Neuropharmacol. 2023. PMID: 37519000 Free PMC article.

3

Can a previously co-designed device be used by others? A service evaluation of the use of the Sativex spray holder for individuals with multiple sclerosis.

Howard J, Bowtell M, Fisher Z, Tasker LH, Tree JJ. Howard J, et al. Disabil Rehabil Assist Technol. 2024 May;19(4):1700-1708. doi: 10.1080/17483107.2023.2228344. Epub 2023 Jun 24. Disabil Rehabil Assist Technol. 2024. PMID: 37354541

4

Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.

Nicholas J, Lublin F, Klineova S, Berwaerts J, Chinnapongse R, Checketts D, Javaid S, Steinerman JR. Nicholas J, et al. Mult Scler Relat Disord. 2023 Jul;75:104745. doi: 10.1016/j.msard.2023.104745. Epub 2023 May 1. Mult Scler Relat Disord. 2023. PMID: 37209500 Free article. Clinical Trial.

5

Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study.

Torri Clerici V, Brambilla L, Politi PL, Viggiani F, Mercurio S, Tonietti S, Ronzoni M, Crisafulli SG, Antozzi C, Tramacere I, Redemagni C, Confalonieri P. Torri Clerici V, et al. Mult Scler Relat Disord. 2023 Jun;74:104711. doi: 10.1016/j.msard.2023.104711. Epub 2023 Apr 9. Mult Scler Relat Disord. 2023. PMID: 37062198 Free article.

6

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity.

Gajofatto A, Cardobi N, Gobbin F, Calabrese M, Turatti M, Benedetti MD. Gajofatto A, et al. BMC Neurol. 2023 Mar 29;23(1):128. doi: 10.1186/s12883-023-03171-0. BMC Neurol. 2023. PMID: 36991352 Free PMC article.

7

Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.

Guger M, Hatschenberger R, Leutmezer F. Guger M, et al. Brain Behav. 2023 Apr;13(4):e2947. doi: 10.1002/brb3.2947. Epub 2023 Mar 19. Brain Behav. 2023. PMID: 36934456 Free PMC article.

8

CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.

Müller-Vahl KR, Pisarenko A, Szejko N, Haas M, Fremer C, Jakubovski E, Musil R, Münchau A, Neuner I, Huys D, van Elst LT, Schröder C, Ringlstetter R, Koch A, Jenz EB, Großhennig A. Müller-Vahl KR, et al. Psychiatry Res. 2023 May;323:115135. doi: 10.1016/j.psychres.2023.115135. Epub 2023 Feb 28. Psychiatry Res. 2023. PMID: 36878177 Free article. Clinical Trial.

9

Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study.

Pau M, Porta M, Spinicci G, Frau J, Lorefice L, Coghe G, Cocco E. Pau M, et al. Neurol Sci. 2023 Feb;44(2):685-691. doi: 10.1007/s10072-022-06456-3. Epub 2022 Oct 19. Neurol Sci. 2023. PMID: 36260259 Free PMC article. Clinical Trial.

10

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.

Mills L, Dunlop A, Montebello M, Copeland J, Bruno R, Jefferies M, Mcgregor I, Lintzeris N. Mills L, et al. Subst Abuse Treat Prev Policy. 2022 Oct 8;17(1):67. doi: 10.1186/s13011-022-00493-z. Subst Abuse Treat Prev Policy. 2022. PMID: 36209081 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

235 results

Results by year